What is the current Imatinib Drug market size?

The Imatinib Drug market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Imatinib Drug market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Imatinib Drug market?

Key drivers include rising cancer incidence and growing adoption of targeted therapies.

What are the major challenges facing the Imatinib Drug market?

Challenges include high development costs and increasing competition from generic drugs.

Which regions lead the Imatinib Drug market?

North America and Europe are regional leaders, driven by strong healthcare infrastructure.

Who are the top companies in the Imatinib Drug market?

Top companies include Novartis, Pfizer, and GlaxoSmithKline, with a strong pipeline of products.

What future opportunities exist in the Imatinib Drug market?

Future opportunities include emerging markets and increasing use of Imatinib in new cancer treatments.

How will technology impact the Imatinib Drug market?

Technology will drive innovation, with advances in precision medicine and personalized healthcare.

What is the regulatory landscape for the Imatinib Drug market?

The regulatory landscape is evolving, with a focus on safety, efficacy, and cost-effectiveness.

What is the future outlook for the Imatinib Drug market?

The future outlook is positive, with growing demand and increasing investment in research and development.

Imatinib Drug Growth Trends & Opportunity Analysis 2033

Imatinib Drug by Application (Chronic Myelogenous Leukemia, Gastrointestinal Stromal Tumors, Others), by Types (Tablets, Capsules), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2899 million

CAGR: 3.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2899 million

CAGR: 3.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Imatinib Drug Market Overview

The Imatinib Drug market refers to the global marketplace for the medication Imatinib, which is primarily used to treat certain types of cancer, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). As a key component of the global pharmaceutical industry, the Imatinib Drug market size is significant, with a current estimated value of approximately $4.7 billion. The growth outlook for this market is positive, driven by increasing demand for targeted cancer therapies, with a market forecast indicating a compound annual growth rate (CAGR) of around 7% over the forecast period from 2026 to 2033. This industry expansion can be attributed to advancements in medical technology, evolving consumer behavior towards healthcare, and stringent regulations governing the pharmaceutical sector.

Loading chart…

The Imatinib Drug market is influenced by several key forces, including technology shifts towards more personalized medicine, regulations that impact drug development and approval processes, and changes in consumer behavior that prioritize health and wellness. The largest region for Imatinib Drug sales is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by expanding healthcare infrastructure and increasing cancer prevalence. As the pharmaceutical industry continues to evolve, understanding these dynamics will be crucial for strategic planners and business development teams seeking to capitalize on emerging opportunities within the Imatinib Drug market.

Report Overview

Report Attribute	Details
Market size value in 2025	2.90 billion
Revenue forecast in 2033	5.06 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Glenmark Pharmaceuticals Ltd.; Sun Pharmaceuticals; Actavis Generics; Dr. Reddy's Laboratories; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; Cipla Inc.; Apotex Inc.; Mylan Pharms Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Imatinib Drug market is poised for significant growth, driven by increasing demand for targeted therapies and rising incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

Growth Drivers2 items

Rising awareness about the benefits of Imatinib Drug among patients and healthcare professionals, leading to increased adoption and Imatinib Drug market size expansion

Ongoing research and development activities focused on improving treatment outcomes and exploring new indications, contributing to a positive growth forecast

Restraints2 items

High costs associated with Imatinib Drug treatment, making it inaccessible to a significant portion of the patient population, particularly in developing economies

Stringent regulatory frameworks and intense competition from generic versions of the drug, which may hinder the growth forecast of the Imatinib Drug market

Opportunities2 items

Expanding Imatinib Drug market size in emerging economies, driven by increasing healthcare expenditure and improving access to cancer treatments

Growing demand for personalized medicine and targeted therapies, creating opportunities for pharmaceutical companies to develop innovative Imatinib Drug formulations and combination treatments

Challenges2 items

Managing the side effects and toxicity associated with Imatinib Drug treatment, which can impact patient adherence and overall treatment outcomes

Addressing the patent expiry of key Imatinib Drug products and the subsequent entry of generic versions, which may lead to pricing pressures and reduced revenue for pharmaceutical companies

Market Segmentation

Loading chart…

The Imatinib Drug market can be segmented based on application, which refers to the specific use cases of Imatinib in the treatment of various diseases. This segmentation is crucial in understanding the Imatinib Drug segmentation and its impact on the overall market size. The application segment includes the treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST), among others. Each application contributes to the overall market size, with CML being the largest contributor due to the high prevalence of the disease.

In terms of types, the Imatinib Drug market can be further segmented into Imatinib Mesylate and Imatinib Base. Imatinib Mesylate is the most commonly used type, accounting for a significant share of the market. The types segment is important in understanding the market taxonomy of Imatinib, as it affects the pricing, distribution, and marketing strategies of manufacturers. Each type has its own set of advantages and disadvantages, which influence the purchasing decisions of healthcare providers and patients.

Imatinib Drug Segmentation Breakdown7 items

Application

Chronic Myelogenous Leukemia

Gastrointestinal Stromal Tumors

Others

Types

Tablets

Capsules

Regional Insights

Loading chart…

The Imatinib Drug market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the global market, driven by key drivers such as increasing adoption of Imatinib drugs, favorable policies supporting pharmaceutical innovation, and significant investments in healthcare infrastructure. The fastest-growing region is expected to be Latin America, driven by growing demographics and an improving ecosystem maturity.

In North America, key drivers include a mature ecosystem, high adoption rates, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and a high level of ecosystem maturity. In Asia Pacific, drivers include increasing adoption, growing demographics, and significant investments in healthcare. In Latin America, drivers include growing demographics, improving ecosystem maturity, and increasing adoption. In Middle East & Africa, drivers include growing demographics, improving infrastructure, and increasing investments in healthcare.

The regional forecast indicates that the Imatinib Drug market will continue to grow, driven by these key drivers and factors. As the market evolves, it is essential to monitor regional trends and market growth to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Imatinib Drug market is moderately consolidated, driven by a mix of global players and local companies. The Imatinib Drug competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local companies concentrate on pricing and distribution to gain market share.

Companies in the Imatinib Drug market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on technology, service model, channel strength, customization, and cost advantages to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategies to navigate the market:

Novartis: regional expansion

Glenmark Pharmaceuticals Ltd.: vertical integration

Sun Pharmaceuticals: premium pricing

Actavis Generics: OEM tie-ups

Dr. Reddy's Laboratories: innovation pipeline

Teva Pharmaceutical Industries Ltd.: local manufacturing

Key Imatinib Drug Companies10 items

Novartis

Glenmark Pharmaceuticals Ltd.

Sun Pharmaceuticals

Actavis Generics

Dr. Reddy's Laboratories

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Cipla Inc.

Apotex Inc.

Mylan Pharms Inc.

Market Ecosystem

The Imatinib Drug ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Imatinib Drug products, with each segment influencing the overall efficiency and effectiveness of the ecosystem.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing Imatinib Drug products

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — enforcing quality and safety standards

Data/analytics providers — providing insights on treatment outcomes and market trends

In the Imatinib Drug ecosystem, control points are held by regulators, who influence adoption through approvals and standards. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards, which can impact manufacturing and distribution. Switching costs and partnerships can also affect the ecosystem, particularly in terms of interoperability requirements between different products and services. Furthermore, the ecosystem differs by region, with varying regulatory frameworks and market dynamics impacting the flow of value through the Imatinib Drug ecosystem.

Recent Industry Insights

The Imatinib Drug industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have enabled companies to expand their product portfolios and enhance their research capabilities. Notably, several mergers and acquisitions have taken place, leading to market consolidation and increased competition. Furthermore, the launch of new formulations and technologies has improved treatment outcomes for patients. Regulatory changes have also had a profound impact on the industry, with a greater emphasis on safety and efficacy. A shift in consumer trends towards personalized medicine has driven the demand for targeted therapies, including Imatinib. Additionally, funding rounds and expansions have provided companies with the necessary resources to invest in research and development, paving the way for future growth and innovation in the Imatinib Drug market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Imatinib Drug market. The Imatinib Drug market outlook is promising, driven by increasing demand for targeted therapies. The market attractiveness is moderate, with a competitive intensity that is relatively high due to the presence of established players. The long-term outlook is favorable, with opportunities for innovation in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.

The innovation landscape is evolving, with a focus on developing next-generation tyrosine kinase inhibitors. The demand-supply balance is expected to remain stable, with key risk factors including regulatory changes and patent expirations. Overall, the Imatinib Drug market is expected to experience steady growth, driven by increasing adoption of precision medicine approaches.

12 items

1. Executive Summary

2. Imatinib Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Imatinib Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Imatinib Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Imatinib Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Imatinib Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Imatinib Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Imatinib Drug Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Imatinib Drug Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Imatinib Drug Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Imatinib Drug Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Imatinib Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Imatinib Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Imatinib Drug Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Imatinib Drug Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Imatinib Drug Market Competition by Key Manufacturers

9.1. Global Imatinib Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Imatinib Drug: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novartis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Glenmark Pharmaceuticals Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Sun Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Actavis Generics

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Dr. Reddy's Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Teva Pharmaceutical Industries Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Sanofi S.A.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Cipla Inc.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Apotex Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Mylan Pharms Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Imatinib Drug Market

Figure 4: Global Imatinib Drug Market: Drivers

Figure 5: Global Imatinib Drug Market: Challenges

Figure 6: Global Imatinib Drug Market: Trends

Figure 7: Global Imatinib Drug Market: Opportunity

Figure 8: Global Imatinib Drug Market: Restraint

Figure 9: Global Imatinib Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Imatinib Drug Market Value (USD Million) By Region

Figure 19: Global Imatinib Drug Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Imatinib Drug Market Value (USD Million) By Region

Figure 27: Global Imatinib Drug Market Share (%) By: Regions (2032)

Figure 28: Global Imatinib Drug Market Volume (K) By Region

Figure 29: Global Imatinib Drug Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Imatinib Drug Market Value (USD Million) By Region

Figure 37: Global Imatinib Drug Market Share (%) By: Regions (2032)

Figure 38: Global Imatinib Drug Market Volume (K) By Region

Figure 39: Global Imatinib Drug Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Imatinib Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Imatinib Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Imatinib Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Imatinib Drug Market Value (USD Million) By Region

Table 14: Global Imatinib Drug Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Imatinib Drug Market Volume (K) By Region

Table 31: Global Imatinib Drug Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Imatinib Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Imatinib Drug Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Imatinib Drug Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novartis Basic Information And Sales Area

Table 52: Novartis. Products Portfolio

Table 53: Glenmark Pharmaceuticals Ltd. Basic Information And Sales Area

Table 54: Glenmark Pharmaceuticals Ltd.. Products Portfolio

Table 55: Sun Pharmaceuticals Basic Information And Sales Area

Table 56: Sun Pharmaceuticals. Products Portfolio

Table 57: Actavis Generics Basic Information And Sales Area

Table 58: Actavis Generics. Products Portfolio

Table 59: Dr. Reddy's Laboratories Basic Information And Sales Area

Table 60: Dr. Reddy's Laboratories. Products Portfolio

Table 61: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 62: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 63: Sanofi S.A. Basic Information And Sales Area

Table 64: Sanofi S.A.. Products Portfolio

Table 65: Cipla Inc. Basic Information And Sales Area

Table 66: Cipla Inc.. Products Portfolio

Table 67: Apotex Inc. Basic Information And Sales Area

Table 68: Apotex Inc.. Products Portfolio

Table 69: Mylan Pharms Inc. Basic Information And Sales Area

Table 70: Mylan Pharms Inc.. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Imatinib Drug Market Value (USD Million) By Region

Table 80: Global Imatinib Drug Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Imatinib Drug Market Volume (K) By Region

Table 97: Global Imatinib Drug Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Imatinib Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.90 billion
Revenue forecast in 2033	5.06 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Glenmark Pharmaceuticals Ltd.; Sun Pharmaceuticals; Actavis Generics; Dr. Reddy's Laboratories; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; Cipla Inc.; Apotex Inc.; Mylan Pharms Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising awareness about the benefits of Imatinib Drug among patients and healthcare professionals, leading to increased adoption and Imatinib Drug market size expansion

Ongoing research and development activities focused on improving treatment outcomes and exploring new indications, contributing to a positive growth forecast

Restraints2 items

High costs associated with Imatinib Drug treatment, making it inaccessible to a significant portion of the patient population, particularly in developing economies

Stringent regulatory frameworks and intense competition from generic versions of the drug, which may hinder the growth forecast of the Imatinib Drug market

Opportunities2 items

Expanding Imatinib Drug market size in emerging economies, driven by increasing healthcare expenditure and improving access to cancer treatments

Growing demand for personalized medicine and targeted therapies, creating opportunities for pharmaceutical companies to develop innovative Imatinib Drug formulations and combination treatments

Challenges2 items

Managing the side effects and toxicity associated with Imatinib Drug treatment, which can impact patient adherence and overall treatment outcomes

Addressing the patent expiry of key Imatinib Drug products and the subsequent entry of generic versions, which may lead to pricing pressures and reduced revenue for pharmaceutical companies

Market Segmentation

Loading chart…

Imatinib Drug Segmentation Breakdown7 items

Application

Chronic Myelogenous Leukemia

Gastrointestinal Stromal Tumors

Others

Types

Tablets

Capsules

Regional Insights

Loading chart…

Competitive Landscape

Novartis: regional expansion

Glenmark Pharmaceuticals Ltd.: vertical integration

Sun Pharmaceuticals: premium pricing

Actavis Generics: OEM tie-ups

Dr. Reddy's Laboratories: innovation pipeline

Teva Pharmaceutical Industries Ltd.: local manufacturing

Key Imatinib Drug Companies10 items

Novartis

Glenmark Pharmaceuticals Ltd.

Sun Pharmaceuticals

Actavis Generics

Dr. Reddy's Laboratories

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Cipla Inc.

Apotex Inc.

Mylan Pharms Inc.

Market Ecosystem

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing Imatinib Drug products

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — enforcing quality and safety standards

Data/analytics providers — providing insights on treatment outcomes and market trends

Recent Industry Insights

Analyst Overview

Table of Contents